Noxopharm (ASX:NOX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NOX 주식 개요

호주에서 암과 염증 치료제와 mRNA 백신을 발견하고 개발하는 생명공학 회사인 Noxopharm Limited는 암과 염증 치료제를 연구하고 개발합니다.

NOX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

위험 분석

cash runway 경력이 1년 미만입니다.

지난 5년간 매년 수익이 14.4% 씩 감소했습니다.

의미 있는 시가총액이 없습니다. ( A$20M )

최근 3개월간 주가 변동성

+ 1 더 많은 위험

Noxopharm Limited 경쟁사

Radiopharm Theranostics

ASX:RAD

AU$17.5m

Chimeric Therapeutics

ASX:CHM

AU$17.3m

AdAlta

ASX:1AD

AU$15.5m

Tissue Repair

ASX:TRP

AU$13.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Noxopharm
과거 주가
현재 주가	AU$0.066
52주 최고치	AU$0.17
52주 최저치	AU$0.033
베타	0.67
11개월 변경	-17.50%
3개월 변경 사항	-1.49%
1년 변경 사항	53.49%
33년 변화	-90.50%
5년 변화	-86.25%
IPO 이후 변화	-64.32%

최근 뉴스 및 업데이트

Recent updates

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 17

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Sep 04

주주 수익률

	NOX	AU Biotechs	AU 마켓
7D	-17.5%	0.6%	-0.3%
1Y	53.5%	7.6%	8.3%

수익률 대 산업: NOX 지난 1년 동안 4.2 %를 반환한 Australian Biotechs 산업을 초과했습니다.

수익률 대 시장: NOX 지난 1년 동안 6.7 %를 반환한 Australian 시장을 초과했습니다.

가격 변동성

Is NOX's price volatile compared to industry and market?
NOX volatility
NOX Average Weekly Movement	13.2%
Biotechs Industry Average Movement	11.8%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	3.2%

안정적인 주가: NOX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: NOX 의 주간 변동성은 지난 1년 동안 20% 에서 13% 로 감소했지만 여전히 Australian 주식의 75%보다 높습니다.

회사 소개

설립	직원	CEO	웹사이트
2015	n/a	Gisela Mautner	www.noxopharm.com

호주에서 암과 염증 치료제와 mRNA 백신을 발견하고 개발하는 생명공학 회사인 Noxopharm Limited. 주로 고형 종양 치료를 위한 이드로녹실 제제인 베요다를 개발합니다. 또한 말기 전립선암 치료를 위한 베요다와 177Lu-PSMA-617의 병용 요법인 루핀과 다양한 고형 종양 치료를 위해 베요다와 브리스톨 마이어스 스퀴브의 체크포인트 억제제 옵디보를 결합한 이온 프로그램을 개발합니다.

Noxopharm Limited 기본 사항 요약

Noxopharm 의 수익과 매출은 시가총액과 어떻게 비교하나요?
NOX 기본 통계
시가총액	AU$19.29m
수익(TTM)	-AU$12.13m
수익(TTM)	AU$3.88m

5.0x

P/S 비율

-1.6x

P/E 비율

NOX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
NOX 손익 계산서(TTM)
수익	AU$3.88m
수익 비용	AU$6.30m
총 이익	-AU$2.43m
기타 비용	AU$9.70m
수익	-AU$12.13m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.041
총 마진	-62.60%
순이익 마진	-312.86%
부채/자본 비율	0%

NOX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

NOX 주식 개요

보상

위험 분석

Noxopharm Limited 경쟁사

ASX:RAD

AU$17.5m

ASX:CHM

AU$17.3m

ASX:1AD

AU$15.5m

ASX:TRP

AU$13.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

New major risk - Market cap size

New major risk - Share price stability

New major risk - Financial position

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Non-Executive Chairman recently bought AU$50k worth of stock

Recent updates

New major risk - Market cap size

New major risk - Share price stability

New major risk - Financial position

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Non-Executive Chairman recently bought AU$50k worth of stock

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

No independent directors

Insider recently sold AU$278k worth of stock

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Full year 2022 earnings released: AU$0.064 loss per share (vs AU$0.035 loss in FY 2021)

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

No independent directors

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Full year 2021 earnings released: AU$0.035 loss per share (vs AU$0.002 loss in FY 2020)

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Founder exercised options to buy AU$5.5m worth of stock.

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

New 90-day high: AU$0.69

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

Noxopharm Limited Provides Update on Its Ongoing New Immuno-Oncology Drug

Noxopharm Limited Announces Independent Discovery Validates Darrt Cancer Therapy

New 90-day high: AU$0.54

Noxopharm Limited Announce Partnership with Hudson Institute of Medical Research and Australian National University for the Formation of the New Australian Drug Development Company

New 90-day high: AU$0.44

Noxopharm Limited Announces the Final Patient Has Completes Treatment in the Lupin Study

Noxopharm Announces First COVID-19 Patient Treated in Veyonda Study

Noxopharm Limited Announces the Enrolment and Treatment of the First Patient into the Phase 1 NOXCOVID-1

New 90-day high: AU$0.39

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

주주 수익률